Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC fiscal 2009 request

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission requests $256.2 million for its fiscal 2009 budget, an increase of $12.3 million that would support 18 additional FTEs, including 10 to work on consumer protection issues, according to information prepared for President Bush's budget request issued Feb. 4. FTC says it will continue to investigate deceptive marketing of health products, particularly those making disease prevention or weight-loss claims. As an example of its enforcement work, FTC cited the January 2007 settlements reached following investigations of false or unsubstantiated claims by marketers of Xenadrine EFX,CortiSlim,TrimSpa and One-A-Day WeightSmart (1"The Tan Sheet" Jan. 8, 2007, p. 4). The commission says it will continue to focus on health care products, including dietary supplements, "focusing its law enforcement on violations that create the greatest risks to consumer health"...

You may also be interested in...



FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action

Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Topics

UsernamePublicRestriction

Register

PS101368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel